کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2999509 | 1180291 | 2011 | 19 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
VA-HITFenofibrate Intervention and Event Lowering in DiabetesHDLCHDACCORDIDLVLDLRCThigh-density lipoprotein - HDL یا لیپوپروتئین با دانسیته بالا یا چگالی بالاATP - آدنوزین تری فسفات یا ATPRandomized controlled trial - آزمایش تصادفی کنترل شدهMyocardial infarction - آنفارکتوس میوکاردapo - آپوapolipoprotein - آپولیپوپروتئینAction to Control Cardiovascular Risk in Diabetes - اقدام برای کنترل خطر قلبی عروقی در دیابتcoronary heart disease - بیماری عروق کرونر قلبtriglyceride - تریگلیسریدDiabetes mellitus - دیابت قندیField - رشتهconfidence interval - فاصله اطمینانvery low-density lipoprotein - لیپوپروتئین بسیار کم چگالیIntermediate-density lipoprotein - لیپوپروتئین چگالی متوسطLow-density lipoprotein - لیپوپروتئین کم چگالی یا الدیال LDL - لیپوپروتئین کم چگالی(کلسترول بد)hazard ratio - نسبت خطرAdult Treatment Panel - پانل درمان بزرگسالانFats - چربی ها
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) represent the cornerstone of drug therapy to reduce low-density lipoprotein (LDL) cholesterol and cardiovascular risk. However, even optimal statin management of LDL cholesterol leaves many patients with residual cardiovascular risk, in part because statins are more effective in reducing LDL cholesterol than apolipoprotein B (Apo B). Apo B may be a better marker of atherogenic risk than LDL cholesterol because Apo B measures the total number of all atherogenic particles (total atherosclerotic burden), including LDL, very low-density lipoprotein, intermediate-density lipoprotein, remnant lipoproteins, and lipoprotein(a). To determine whether Apo B is a better indicator of baseline cardiovascular risk and residual risk after lipid therapy compared with LDL cholesterol, a MEDLINE search of the literature published in English from January 1, 1975, through December 1, 2010, was conducted. On the basis of data from most population studies, elevated Apo B was more strongly associated with incident coronary heart disease than similarly elevated LDL cholesterol. Apo B was also a superior benchmark (vs LDL cholesterol) of statins' cardioprotective efficacy in both primary-prevention and secondary-prevention trials. To minimize cardiovascular risk among persons with hypercholesterolemia or dyslipidemia, the best available evidence suggests that intensive therapy with statins should be initiated to achieve the lowest possible Apo B level (with adequate drug toleration) and then other therapies (eg, niacin, bile acid resins, ezetimibe) added to potentiate these Apo B-lowering effects. In future consensus lipid-lowering treatment guidelines, Apo B should be considered as an index of residual risk, a potential parameter of treatment efficacy, and a treatment target to minimize risk of coronary heart disease.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 86, Issue 8, August 2011, Pages 762-780
Journal: Mayo Clinic Proceedings - Volume 86, Issue 8, August 2011, Pages 762-780
نویسندگان
Terry A. MD,